BioCardia Inc. (NASDAQ: BCDA) President and CEO Peter Altman executed a stock purchase on June 9, 2026, acquiring 5,000 shares at $0.85 per share, totaling $4,250. This transaction occurred just above the stock's 52-week low of $0.84 and follows a period where the share price has declined 59% over the past year. Following the purchase, Altman's direct ownership in the biotechnology company's common stock rose to 298,266 shares. BioCardia, headquartered in Sunnyvale, California, is currently trading near its fair value according to InvestingPro analysis.
The company recently completed a capital raise of approximately $4.5 million through the sale of 3,509,604 shares at an average price of $1.279, without issuing warrants. Regulatory developments include significant feedback from the FDA regarding the CardiAMP Heart Failure II Trial, which may support Premarket Approval for the CardiAMP Cell Therapy System. Additionally, Japan's Pharmaceutical and Medical Device Agency acknowledged the credibility of positive outcomes from three completed clinical trials, supporting the planned submission for regulatory approval. The company also reported positive results from its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial, demonstrating increased exercise tolerance and reduced angina episodes in patients.
The executive's purchase comes as BioCardia navigates a critical phase in its therapeutic development pipeline. The acquisition of shares by the CEO, occurring at a price point just above the 52-week low, provides a signal regarding internal valuation perceptions. The transaction increased his direct stake to 298,266 shares, reflecting continued alignment with shareholder interests despite the stock's 59% decline over the past year.
Financially, the company's recent capital raise of $4.5 million, achieved through the sale of 3,509,604 shares at $1.279, provides essential liquidity for ongoing operations. The absence of warrant issuance in this transaction suggests a straightforward equity financing structure. Trading data indicates the stock closed at $0.86, down $0.060 or 6.55%, with after-hours trading showing a further decline to $0.84, down $0.020 or 2.29%.
Regulatory milestones represent a significant component of the company's current strategic focus. The FDA's feedback on the CardiAMP Heart Failure II Trial is pivotal, as Premarket Approval constitutes the most stringent device marketing application pathway. Concurrently, Japan's Pharmaceutical and Medical Device Agency has validated the credibility of positive clinical trial outcomes, facilitating the planned submission for regulatory approval. These developments are compounded by positive results from the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial, which showed increased exercise tolerance and reduced angina episodes in patients.